Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Recommendation of “Moderate Buy” from Analysts

by · The Cerbat Gem

Shares of Alto Neuroscience, Inc. (NYSE:ANRO – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $35.25.

Several research analysts have recently commented on the company. Wolfe Research assumed coverage on Alto Neuroscience in a research report on Friday, May 22nd. They set an “outperform” rating for the company. Robert W. Baird lowered their price target on Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. Bank of America began coverage on Alto Neuroscience in a research note on Tuesday, May 5th. They issued a “buy” rating and a $35.00 price objective on the stock. HC Wainwright reiterated a “buy” rating on shares of Alto Neuroscience in a research note on Wednesday. Finally, Wall Street Zen cut Alto Neuroscience from a “hold” rating to a “strong sell” rating in a research note on Sunday, May 17th.

Read Our Latest Stock Analysis on ANRO

Alto Neuroscience Trading Down 0.3%

ANRO opened at $22.68 on Friday. Alto Neuroscience has a 52 week low of $2.15 and a 52 week high of $28.44. The business has a fifty day simple moving average of $22.73 and a 200-day simple moving average of $19.80. The firm has a market cap of $795.77 million, a P/E ratio of -9.37 and a beta of 1.22. The company has a quick ratio of 20.52, a current ratio of 20.52 and a debt-to-equity ratio of 0.07.

Alto Neuroscience (NYSE:ANRO – Get Free Report) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.24). On average, equities analysts expect that Alto Neuroscience will post -3.01 earnings per share for the current year.

Institutional Trading of Alto Neuroscience

Hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC acquired a new stake in shares of Alto Neuroscience in the first quarter valued at $52,000. Torren Management LLC acquired a new stake in shares of Alto Neuroscience in the fourth quarter valued at $62,000. Invesco Ltd. acquired a new stake in shares of Alto Neuroscience in the first quarter valued at $67,000. Bridgeway Capital Management LLC raised its stake in shares of Alto Neuroscience by 85.9% in the second quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock valued at $119,000 after acquiring an additional 25,000 shares in the last quarter. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Alto Neuroscience in the fourth quarter valued at $198,000.

Alto Neuroscience Company Profile

(Get Free Report)

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.

Read More